Compare VNRX & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | NVNO |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 6.8M |
| IPO Year | 2012 | 2017 |
| Metric | VNRX | NVNO |
|---|---|---|
| Price | $0.31 | $9.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.67 | N/A |
| AVG Volume (30 Days) | ★ 9.7M | 21.7K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,727,384.00 | $31,243.00 |
| Revenue This Year | $355.66 | N/A |
| Revenue Next Year | $849.08 | $140.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40.04 | N/A |
| 52 Week Low | $0.13 | $0.30 |
| 52 Week High | $3.26 | $13.44 |
| Indicator | VNRX | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 28.70 | 42.73 |
| Support Level | $0.30 | $9.96 |
| Resistance Level | $0.39 | $11.40 |
| Average True Range (ATR) | 0.05 | 0.70 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 1.04 | 13.64 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.